LUMOS PHARMA reduces its risk exposure and slightly improves to Neutral
The independent financial analyst theScreener just allocated a lower risk rating to LUMOS PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly improved and can be qualified as moderately risky. theScreener considers that these elements merit an overall rating upgrade to Neutral. As of the analysis date February 22, 2022, the closing price was USD 9.98 and its expected value was estimated at USD 8.69.Lumos Pharma is a clinical-stage immuno-oncology company develops immunotherapeutic products for the treatment of patients with cancer. The company's small-molecule product candidates in clinical development target the indoleamine-2, 3-dioxygenase (IDO) pathway, which is a pathway for cancer immune escape. These product candidates, indoximod and NLG802 (a prodrug of indoximod), are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system's tolerance to cancer. The company's small molecule product candidate, NLG207, which is a nanoparticle-drug conjugate, consisting of a cyclodextrin-based polymer backbone linked to camptothecin, a topoisomerase 1 inhibitor.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.